Skip to content
Congress·In Committee·about 1 month ago

Senate Bill Would Narrow Rare Disease Drug Monopolies to Specific Approved Uses

Also known as: RARE Act

Legislative Progress

✓ Filed
Review
Senate
House
President

Impact Analysis

Scores: 1 = low, 5 = highSentiment: -5 to +5 (net benefit)

Key Points

  • This bill changes how the government grants "exclusivity" to companies that make medicines for rare diseases. Currently, when a company gets a drug approved for a rare disease, they often get 7 years where no one else can sell a drug for that entire disease. This bill limits that protection to only the specific use the drug was approved for.
  • Patients with rare diseases could see more treatment options and lower costs. By narrowing the rules, other companies can bring different treatments for the same disease to market much faster instead of being blocked by a broad 7-year "monopoly" on the entire condition.
  • This plan aims to fix a problem where one company could stop others from helping patients, even if the new medicine works differently or treats a different part of the illness. It encourages more companies to research rare diseases by making sure one drug doesn't block all others.
  • These changes would apply to all rare disease drugs, regardless of when they were first approved or designated. This means even drugs currently on the market would have their protections narrowed to match their specific approved uses.
Healthcare

Milestones

2 milestones2 actions
Jan 28, 2026Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Jan 28, 2026

Introduced in Senate

Related News

3 articles
American Action Forum·about 1 month ago

Health Care Extenders: Key Provisions in the Consolidated Appropriations Act, 2026

The legislation revises how Orphan Drug exclusivity is applied, changing the standard from the 'same disease or condition' to the 'same approved use or indication.' This allows generic competitors to market drugs for new uses or patient populations sooner.

CR=
AHA News·about 2 years ago

Hospitals testify on proposals to support patients with rare diseases

During a House hearing, medical experts urged Congress to advance the Retaining Access and Restoring Exclusivity (RARE) Act, which would limit orphan drug exclusivity to the approved indication to encourage market competition and lower costs for rare disease treatments.

C=
FDA Law Blog·13 days ago

Rare Disease Month Developments: RPD PRV Program Renewed, Orphan Drug Exclusivity Clarified

The Consolidated Appropriations Act, 2026, codifies the FDA's longstanding interpretation of the Orphan Drug Act by limiting the scope of seven-year exclusivity to the indication ultimately approved, effectively reversing the controversial Catalyst v. Becerra court decision.

=

Source Information

Document Type

Congressional Bill

Official Title

RARE Act

Bill NumberS 3716
Congress119th Congress
ChamberSenate
Latest ActionRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsor

Analysis generated by AI. While we strive for accuracy, this should not be considered legal or professional advice. Always verify information with official government sources.